Kyowa Kirin Co., Ltd.
4151
Peringkat dalam Saham
#2395
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Harga Saham
$15.72
Kapitalisasi Pasar
$8.23B
Perubahan (1 hari)
1.52%
Perubahan (1 tahun)
4.65%
Negara
JP
Perdagangan Kyowa Kirin Co., Ltd. (4151)
Kategori
Healthcare
Rasio P/E untuk Kyowa Kirin Co., Ltd. (4151)
Rasio P/E per October 2026 TTM: 14.82
Menurut laporan keuangan dan harga saham terbaru dari Kyowa Kirin Co., Ltd., rasio P/E saat ini (TTM) adalah 14.82. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 21.01.
Riwayat rasio P/E untuk Kyowa Kirin Co., Ltd. dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 14.82 | -24.91% |
| 2025 | 19.73 | -6.09% |
| 2024 | 21.01 | 33.89% |
| 2023 | 15.69 | -48.20% |
| 2022 | 30.30 | -5.84% |
| 2021 | 32.18 | 0.12% |
| 2020 | 32.14 | -12.62% |
| 2019 | 36.78 | 78.93% |
| 2018 | 20.56 | -26.05% |
| 2017 | 27.80 | -41.32% |
| 2016 | 47.37 | 34.58% |
| 2015 | 35.20 | -10.00% |
| 2014 | 39.11 | 85.42% |
| 2013 | 21.09 | 9.62% |
| 2012 | 19.24 | -7.75% |
| 2011 | 20.86 | -2.79% |
| 2010 | 21.46 | -66.44% |
| 2009 | 63.93 | 296.39% |
| 2008 | 16.13 | -53.66% |
| 2007 | 34.80 | 55.70% |
| 2006 | 22.35 | 14.16% |
| 2005 | 19.58 | -34.03% |
| 2004 | 29.68 | 14.74% |
| 2003 | 25.87 | -52.36% |
| 2002 | 54.29 | 46.46% |
| 2001 | 37.07 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 40.53 | 173.56% |
US
|
|
| 38.50 | 159.84% |
US
|
|
| 79.88 | 439.15% |
US
|
|
| 116.96 | 689.43% |
US
|
|
| 22.25 | 50.17% |
CH
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.